Fiduciary Oversight & Q1 FDA Approvals | Navion March Insights
Prescription for Trouble: Why Employers Must Act Now on Pharmacy Fiduciary Oversight
As lawsuits over pharmacy benefit mismanagement make headlines, employers are facing a new wave of fiduciary risk. Learn why the stakes are rising—and what proactive steps can help avoid costly legal and financial fallout.
2025 FDA Q1 Drug Approvals and Launches to Watch
From Stelara biosimilars to newly approved treatments for Parkinson’s and NF1-PN, Q1 drug approvals are already impacting cost and utilization strategies. Learn how plan sponsors can prepare for formulary changes, rising spend and new management considerations.
Business transformation through leadership, client engagement, and communication.
1wVery informative